- Home
- PRQR vs NVCT Comparison
PRQR vs NVCT Comparison
Compare PRQR & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRQR
- NVCT
- Stock Information
- Founded
- PRQR 2012
- NVCT 2020
- Country
- PRQR Netherlands
- NVCT United States
- Employees
- PRQR N/A
- NVCT N/A
- Industry
- PRQR Biotechnology: Pharmaceutical Preparations
- NVCT Medicinal Chemicals and Botanical Products
- Sector
- PRQR Health Care
- NVCT Health Care
- Exchange
- PRQR Nasdaq
- NVCT Nasdaq
- Market Cap
- PRQR 179.1M
- NVCT 184.9M
- IPO Year
- PRQR 2014
- NVCT 2022
- Fundamental
- Price
- PRQR $2.13
- NVCT $7.52
- Analyst Decision
- PRQR Strong Buy
- NVCT Strong Buy
- Analyst Count
- PRQR 8
- NVCT 3
- Target Price
- PRQR $8.88
- NVCT $17.00
- AVG Volume (30 Days)
- PRQR 362.3K
- NVCT 183.0K
- Earning Date
- PRQR 08-07-2025
- NVCT 08-05-2025
- Dividend Yield
- PRQR N/A
- NVCT N/A
- EPS Growth
- PRQR N/A
- NVCT N/A
- EPS
- PRQR N/A
- NVCT N/A
- Revenue
- PRQR $21,212,711.00
- NVCT N/A
- Revenue This Year
- PRQR N/A
- NVCT N/A
- Revenue Next Year
- PRQR N/A
- NVCT N/A
- P/E Ratio
- PRQR N/A
- NVCT N/A
- Revenue Growth
- PRQR 85.91
- NVCT N/A
- 52 Week Low
- PRQR $1.07
- NVCT $4.44
- 52 Week High
- PRQR $4.62
- NVCT $11.80
- Technical
- Relative Strength Index (RSI)
- PRQR 64.73
- NVCT 33.66
- Support Level
- PRQR $1.89
- NVCT $7.25
- Resistance Level
- PRQR $2.54
- NVCT $8.27
- Average True Range (ATR)
- PRQR 0.14
- NVCT 0.45
- MACD
- PRQR 0.01
- NVCT -0.07
- Stochastic Oscillator
- PRQR 43.06
- NVCT 13.85
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.